Background: The concept of food addiction attracts much interest in the scientific community. Research is mainly based on the Yale Food Addiction Scale (YFAS), a tool developed to assess food addiction. Substance use disorder criteria have been used to develop this scale.
INTRODUCTION
Obesity and eating disorders (EDs) such as binge eating disorder (BED) are an important health concern in our society. Possible similarities between overeating and substance use disorder (SUD) have been discussed for decades, with the first mention of the term "food addiction" given by Theron Randolph in 1956 [1] . In the last 3 years, in the midst of important debates related to behavioral addictions, numerous articles have been published on this topic [2] .
The concept of food addiction (FA) was introduced to describe patterns of specific eating behaviors and excessive consumption based on the hypothesis of similarities between such patterns and addictive behaviors [3] .
*Address correspondence to this author at the Geneva University Hospitals, Rue de Grand-Pré, 70 The definition for FA proposed by Gearhardt et al. [3] emerged by mapping the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnostic criteria for substance dependence to eating behaviors [4] . These include tolerance, withdrawal symptoms, larger amounts consumed than intended, persistent desire or unsuccessful attempts to cut down, much time spent using or recovering from a substance, continual use despite knowledge of consequences, and activities given up due to use of a substance. As in the case of substance use disorder, the presence of 3 of 7 symptoms has been suggested as necessary to define FA, as well as to show clinically significant impairment or distress ( Table 1) . To date, FA is not a clinically recognized disorder, but it has been suggested that addictive-like consumption of processed, hyper-palatable, and energydense foods could influence weight gain and obesity [5] .
The most commonly used and well-known tool to measure so-called FA is the Yale Food Addiction Scale (YFAS).
The first scale was developed in 2009 [3] , consisting of a self-report questionnaire that examines eating behaviors during the past 12 months. The YFAS has good clinical validity [6] and has been translated into different languages. It also has good internal consistency, as well as convergent, discriminant, and incremental validity [3, 7] . Elevated scores on this scale have been linked to obesity, EDs, and binge eating [8] . Criteria for substance dependence according to the text revision of the DSM-IV (DSM-IV-TR [9] (Table 1) were used to develop the items for the questionnaire in the YFAS ( Table 2 ) and adapted to consumption of high fat and sugar foods [3] . This means that the questions were formulated to specifically fit these criteria. However, following diagnostic changes in the fifth edition of the DSM (DSM-5) [10] that introduced measures for a continuum of severity and craving, a new version of the YFAS, the YFAS 2.0, was developed in 2016 that added these new criteria for SUD (Tables 2 and 3). The YFAS has 25 questions that measure 7 SUD criteria and the YFAS 2.0 has 35 questions that measure 11 SUD criteria. A short form of each scale was also developed: the modified YFAS (mYFAS) in 2014 [11] and the mYFAS 2.0 in 2017 [12] . If clinical impairment or distress is not present, the "diagnosis" of FA is not retained in all scales even if other symptoms are present. Scoring is computed according to the explanations reported in Table 4 .
Several reviews have been published on FA. Prevalence varied between 16.2% [13] and 19.9% [14] and was higher in overweight patients [14] and patients seeking weight loss [13] . Burrows [13] found a relationship between the presence of FA and binge eating, as well as between FA and depression and anxiety. Another review examined FA in patients seeking bariatric surgery [15] . The prevalence for this group of patients ranged from 14% to 57.8%. The presence of presurgical FA seems not to be associated with presurgical weight or postsurgical weight outcomes, yet presurgical FA was related to broad levels of psychopathology.
Most reviews assessed the published papers in relation to the results obtained with the YFAS in different populations. However, they did not explore the pertinence of the YFAS for the assessment of so-called FA. In the same way as the developers of the YFAS, other authors used the recommended cut-off of the YFAS to measure the existence of FA in different groups. Possible limitations of such reviews are that the conclusions were based on results of studies without assessment of the meaning of FA. For example, prevalence rates were drawn from the number of persons reaching a given cut-off. However, cut-offs were based on experts' consensus on the number of symptoms. The pertinence of the YFAS symptom count for the assessment of so-called FA was not explored.
The present paper is an attempt to explore the significance of the studies that used the YFAS in relation to the concept of FA. We discuss the results in light of the current debate on behavioral addictions. Due to recent changes in the field (introduction of the YFAS 2.0, the mYFAS, and the DSM-5, as well as the behavioral addiction debate), we focus on the three most recent years (2014-2017).
METHODS
A systematic literature review was undertaken in accordance with the guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [16] ( Table 7) .
Search strategy
The electronic databases PsycINFO, MEDLINE, and PsycARTICLES were searched for empirical studies published between January 2014 and July 2017. The following keywords were used: ("yale food addiction scale" OR "YFAS") AND ("food addiction" OR "behavioral addiction" OR "behavioral addiction" OR "eating behavior" OR "eating behavior" OR "obesity" OR "food" OR "eat" OR "feeding behavior" OR "feeding behavior" OR "food preferences" OR "food habits" OR "body mass index" OR "overeating" OR "hyperphagia" OR "substance-related disorders" OR "binge eating" OR "hedonic eating").
Screen for Eligibility
The titles and abstracts of the studies from the initial search results were screened by two reviewers (LP and YK) independently. After excluding duplicates, articles deemed relevant were downloaded and LP and YK screened the full texts independently to determine eligibility. Articles that were dismissed by only one of the reviewers were downloaded together with articles deemed relevant by both reviewers. Eligibility criteria consisted of (1) adult participants over the age of 18 years and (2) the YFAS used to measure Table 1 . DSM-IV-TR substance dependence criteria. 1 . Substance taken in larger amount and for longer period than intended 2. Persistent desire or repeated unsuccessful attempt to quit 3. Much time/activity to obtain, use, recover 4. Important social, occupational, or recreational activities given up or reduced 5. Use continues despite knowledge of adverse consequences (e.g., failure to fulfill role obligation, use when physically hazardous) 6 . Tolerance (marked increase in amount, marked decrease in effect) 7. Characteristic withdrawal symptoms; substance taken to relieve withdrawal Presence of clinical impairment or significant distress The scoring of YFAS is continuous for the first 16 questions with measures 0 to 4 (0 -never, 1 -once per month, 2 -two or three times per month, 3 -two or three times per week, 4 -four or more times per week). Questions 17 to 25 are answered yes or no.
In YFAS 2.0, all 35 questions are continuous with measures 0 to 7 (0 -never, 1 -less than monthly, 2 -once per month, 3 -two or three times per month, 4 -once per week, 5 -two to three times per week, 6 -four to six times per week, 7 -every day).
Different cut-offs for each question:
Each criterion for SUD has several questions. If one question is positive, the criterion is rated as met and scored as 1. In YFAS, yes-no questions are scored 1 or 0.
Clinical impairment or distress is not added to this symptom count but must be present in all cases. If this is not present, the criteria for food addiction is not met even if other symptoms are present.
For diagnosis with YFAS, the symptom count must be ≥3 out of 7 food addiction criteria and show clinical impairment or distress.
For assessment with YFAS 2.0, the symptom count must be ≥2 out of 11 food addiction criteria and show clinical impairment or distress.
(2-3 symptoms count as mild, 4-5 symptoms as moderate, and 6 or more as severe food addiction)
Abbreviations: YFAS -Yale Food Addiction Scale; YFAS 2.0 -Yale Food Addiction Scale Version 2.0; SUD -substance use disorder.
FA symptoms. Any discrepancies between reviewers concerning manuscript eligibility were resolved after a full analysis of the paper and discussion between the two reviewers.
Data Extraction and Summary
Data from the selected studies were tabulated in the following format: author and publication year, country, type of study, number of subjects, recruitment type, target population, inclusion criteria, participant characteristics, outcome measures, prevalence of FA, number of YFAS symptoms, YFAS outcomes in association with other variables, conclusions, and limitations. The extracted data were summarized by using a narrative approach.
RESULTS

Study Selection
The initial search yielded more than 189 publications. After eliminating duplicates, we screened 140 remaining papers, 10 of which were excluded because they did not treat the topic of FA. After applying the eligibility criteria to these 130 papers, we retained 60 in the final review. The most common reasons for exclusion were that the papers were review articles ( Fig. 1) .
Study Methods and Scale Used
Most of the studies were cross-sectional without controls, but six were cross-sectional case-control studies [17] [18] [19] [20] [21] [22] . Most studies used the older version of the YFAS, seven used the YFAS 2.0 [6, 12, [23] [24] [25] [26] , and three used the shorter mY-FAS, which has only nine questions [11, 27, 28] . Nine studies aimed to validate the YFAS [6, 12, 17, 19, 24, [29] [30] [31] [32] , and two used it to validate another eating scale: the Obsessive Compulsive Eating Scale [33] and the Weight Efficacy Lifestyle Scale [34] .
The Italian studies used an Italian version of the YFAS that included 16 questions instead of 25 [19, 30, [35] [36] [37] . Al-though this version is shorter, it includes a question on each FA criterion, as in the YFAS. This scale's validity has been tested [19] . We do not discuss this scale in detail in this analysis.
The studies all used auto-questionnaires. Half of the studies were done online or on paper without an interviewer present, and the other half were done in clinics or laboratories.
Included Samples
Thirty-three studies examined nonclinical samples (27 used the YFAS and 6 used the YFAS 2.0) and 27 (one of which used the YFAS 2.0) examined clinical samples. Among the clinical studies, 11 analyzed patients who were seeking bariatric surgery [17, 29, 34, [38] [39] [40] [41] [42] [43] [44] [45] , one of which used the YFAS 2.0 [29]. One study included a nonclinical control sample [17] , and one study included a follow-up examination [45] . Nine studies evaluated overweight or obese patients; all but two of these studies [46, 47] included patients who were in weight-loss programs [19, 27, 30, 35, 36, 48, 49] . Three of these studies examined women only [27, 36, 46] , one of which used the YFAS 2.0 [23] . Overall, 18 studies that used the original YFAS and 2 that used the YFAS 2.0 analyzed overweight or obese patients.
In four studies, only patients with EDs were analyzed [50] , three of which included only women [20, 51, 52] . One study examined men with heroin addiction [18] and another patients with type 2 diabetes [53] . One study included only patients with schizophrenia who were mainly being treated with clozapine or quetiapine [54] .
More studies investigated female-only samples [11, 46, 51, [55] [56] [57] [58] (three groups used the same National Health Service cohort of female participants: Flint et al. [14] , Cornelis et al. [56] , Mason et al. [57] ) than male-only samples [18, 59] . A large number of studies (15) examined young participants (students or young adults) [22, 24, 26, 28, 29, 32, 33, 46, 55, [60] [61] [62] [63] [64] [65] , two of these using the YFAS 2.0 [24, 29] .
Definition of FA
All studies used the YFAS or YFAS 2.0 scoring results ( Table 4 ) to define FA. The criteria for FA were determined by a consensus of experts from the substance dependence criteria in the DSM-IV [3, 9] . For the YFAS 2.0, following diagnostic changes in the DSM-5 [10] , measures for a continuum of severity and craving were added. For an FA diagnosis to be retained, individuals had to show clinical impairment or distress.
One-third of the articles reported the percentages of different symptoms measured on the scale, which varied between analyses. As Pursey et al. and Burrows et al. found, the highest scored symptom was generally unsuccessful attempts to cut down [13, 14] . Tolerance and use despite knowledge of adverse consequences were also frequent, followed by activities given up and withdrawal symptoms.
Reported Prevalence of FA
Most studies (26) were done in the United States [6, 11, 12, 26, 27, 32, 38, 41, 42, 45, 47-49, 56-59; 63, 66-72] , 3 of which used the YFAS 2.0 [6, 12, 26] .
For studies that used the original YFAS, the prevalence of FA was as follows. In nonclinical samples, the reported prevalence of FA, according to the criteria defined in Table  4 , ranged from 0% to 25.7%. In the clinical samples, the prevalence ranged from 6.7% to 100% (100% was a sample of patients with bulimia nervosa [BN] ). Most studies on patients with ED analyzed for this review were conducted in clinics in Spain, with the prevalence of FA varying from 72.3% to 90.6%.
For studies that used the YFAS 2.0, the prevalence of FA was as follows. In nonclinical samples, the reported prevalence of FA, according to the criteria defined in Table 4 , ranged from 8.2% to 22.2%. In the clinical prebariatric surgery sample, the prevalence was 47.4% (23) . The YFAS 2.0 allows a continuum of severity. The studies that used this measure found mild FA (2 or 3 symptoms) in 0.7% to 1.7% in nonclinical populations, moderate FA (4 or 5 symptoms) in 1.8% to 4.2%, and severe FA (6 or more symptoms) in 6.6% to 18.9%.
Two studies done in the United States showed differences in race: Berenson et al. found higher YFAS scores in black women than in Hispanic women [56] and Carr et al. reported higher YFAS 2.0 scores in black persons than in white [26] . More analyses were done with female-only samples, but in studies with both sexes, one using the YFAS 2.0 showed a link between FA and female gender [25] , and one reported that women had more YFAS symptoms than did men [26] . In addition, gay and bisexual men showed more YFAS symptoms than did heterosexual men [59].
Association with Body Mass Index (BMI)
Other measures taken simultaneously with the YFAS varied widely. The BMI was most frequently recorded by using self-reported data to calculate the score. The number of YFAS symptoms were positively associated with BMI in a Fig. (1) . Flowchart for study selection. YFAS -Yale Food Addiction Scale; FA -Food addiction. majority (10) of the studies that used the original YFAS [11, 23, 29, 53, 57, 62, 63, 66, [68] [69] [70] 73 ] and in 2 studies that used the YFAS 2.0 [23, 29] . Only three studies did not find this correlation [30, 47, 56] , although one [47] analyzed an obese sample. One study found that the YFAS symptom score was associated with a higher visceral fat level [46] .
Association with Comorbid EDs
EDs were assessed in 12 studies that used the original YFAS [17, 20, 43-45, 50-52; 59, 69, 70, 72] and in 4 that used the YFAS 2.0 [6, 12, 24, 29] . In two studies, a link was shown more frequently than in other studies between FA and BN, as well as between FA and BED ( Table 5 ) [20, 70] . In several studies, a higher YFAS symptom score was associated with higher binge eating scores or binge eating days [31, 35, 38, 41, 69] and in 2 studies [24, 29] , a higher YFAS 2.0 score was associated with the same. Interestingly, FA symptoms according to the YFAS were less frequent after treatment of BN. Hilker et al. [52] reported that FA symptoms according to the YFAS improved following a 6-week psychoeducational treatment program. Meule et al. [51] showed that patients with remitted BN (last episode at least 3 months ago) had a lower prevalence of FA symptoms according to the YFAS after being treated in a specialized center for ED.
Numerous studies included patients who were receiving bariatric surgery. In these patients, the prevalence of FA according to the YFAS reduced after surgery. Sevinçer et al. [40] showed a reduction in the prevalence of FA from 57.8% before surgery to 7.2% at 6-month follow-up after the intervention and 13.7% at 12-month follow-up. The weight loss did not differ in patients with or without FA after surgery. Pepino et al. [42] reported that 93% of patients with FA did not present the criteria after bariatric surgery. These results should be interpreted with caution, as the follow-up was short [15] . The prevalence of FA in prebariatric surgery samples seemed to differ across studies between the United States (14-36%) and Europe (21-57.8%).
Association with Scales Related to EDs
BED was commonly measured, with 11 studies [19, 24, 27, 29-31, 33, 35, 37, 39, 65] using the Binge Eating Scale or assessing binge days, 2 of which used the YFAS 2.0 [24, 29] . A higher YFAS 2.0 symptom score was associated with higher binge eating scores or binge eating days [24, 29] . The Three-Factor Eating Questionnaire, which measures restraint, disinhibition, and hunger, was administered in 3 studies that used the original YFAS [6, 12, 22, 24, 65, 66] and in 3 that used the YFAS 2.0 [6, 12, 24] and was generally but not always positively associated with YFAS scores. Eight studies used an emotional eating or emotional regulation scale [24, 27, 30, 37, 41, 44, 45, 72] one of which used the YFAS 2.0 [24] . Persons with higher YFAS scores showed more difficulties in emotional regulation in one analysis [37] and had higher emotional eating scores in two studies [41, 42] . Higher YFAS scores were associated with the experience of higher levels of craving in four studies [42, 43, 66, 69] . Higher night eating scores were also found in persons with higher YFAS scores [67] .
Two studies reported high reward sensitivity associated with FA as diagnosed by YFAS scores [50, 55] . One study found that these individuals showed a more hedonic response to food [71] .
Comorbid Psychiatric Disorders
Depression and/or anxiety was measured in 13 studies [25, 28, 34, 36, 39, 41, 43, 51, 53, 55, 56, 62, 67] . Higher YFAS scores were linked to more depressive symptoms in five analyses [25, 31, 38, 43, 56] . Persons who scored higher on the YFAS were found to have higher anxiety scores in Table 5 . Binge eating disorder (DSM-5).
Criterion 1
Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:
1. Eating, in a discrete period of time (e.g., within any 2-hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances 2. A sense of lack of control over eating during the episode (e.g., a feeling that one cannot stop eating or control what or how much one is eating) Criterion 2
Binge-eating episodes are associated with three (or more) of the following: two studies [25, 38] . One study found a higher prevalence of FA according to the YFAS in patients with symptoms of post-traumatic stress disorder [58] .
Craving
Food craving was analyzed in eight studies [29, 33, 42, 47, 64, 69] , one of which used the YFAS 2.0 [29], and higher scores were found in individuals with positive results for FA according to the YFAS. One article [64] reported that individuals with lower inhibitory performance to food pictures had higher food craving scores.
Impulsiveness
Impulsiveness was examined in 11 studies [18, 29, 30, 33, 43, 50, 53, 55, 63, 64, 68] , one of which used the YFAS 2.0 [29], by administering the Barratt Impulsiveness Scale or the UPPS-P Impulsivity Scale. Three studies [50, 63, 68] reported correlations between impulsivity on the UPPS-P Impulsivity Scale and higher rates of negative urgency in patients with FA as diagnosed by the YFAS. Four studies [53] , one of which used the YFAS 2.0 [29], found correlations between impulsiveness measured with the Barratt Impulsiveness Scale and the YFAS score. Two studies [29, 43] found that higher YFAS symptoms and a diagnosis of FA were correlated with higher attentional impulsivity scores. One of these studies used the YFAS 2.0 [29] and one [43] included presurgery patients. Raymond and Lovell [53] reported a strong correlation between FA and non-planning impulsivity.
DISCUSSION
Sixty publications that examined FA with the YFAS were included in our analysis. Thirty-three studies examined nonclinical samples and 27 examined clinical samples. Prevalence rates of FA varied by clinical and nonclinical population, as well by country. In general, a higher symptom score was associated with a higher BMI [11, 23, 29, 53, 57, 62, 63, 66, 68, 69, 70, 73] .
The studies that analyzed FA used the YFAS symptom score as a cut-off to define FA in groups of patients, as intended by the authors of the YFAS. Most studies used the YFAS scores, however, without providing information on scoring, with only about one-third of the studies explaining the scoring of the different criteria of the YFAS. Symptoms varied in these studies, but the most common was the inability to cut down or stop eating for studies that used the original YFAS. The YFAS 2.0 allows a continuum of severity and therefore different prevalence rates. It allows detection of mild FA, and, interestingly, severe FA with 6 or more symptoms is the most prevalent with rates between 6.6%and 18.9% in nonclinical populations. Most studies, however, use the predefined cut-off and do not further assess the pertinence of the YFAS symptom count for the assessment of socalled FA.
The studies that examined BED symptoms found a positive correlation between the number of BED symptoms, binge eating days, and higher YFAS scores [19, 24, 27, 29-31, 33, 35, 37, 39, 65] . Examination of the criteria of FA 15 16
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With caution, the authors hypothesize that there may be some limitations related to the YFAS item formulation and some items may need to be interpreted differently. This needs to be investigated in further studies.
The questions used to measure the items taken from SUDs on the YFAS and the newer YFAS 2.0 are partly subjective and socially influenced ( Table 2) . For example, the question "I avoided social situations because people wouldn't approve of how much I ate" is strongly influenced by society's view on eating behavior and obesity. The question "I worried a lot about cutting down on certain types of food, but I ate them anyways" can be considered as cognitive restraint and is a symptom of ED such as anorexia nervosa and BN. We examined each questionnaire topic, considering the differences between the YFAS and the YFAS 2.0, to determine whether the symptom that the scale intends to measure was assessed with the questions asked ( Table 2) .
Some groups are more likely to be influenced by social standards about which kind of behavior is expected when considering nutrition and health. Typically, women are often more preoccupied with these topics and are more likely to feel guilty about their eating behaviors. More of the studies in this review were done with female populations (patients and students) than with male populations, which is likely to influence FA prevalence rates. An example of this possibility is that people who self-perceive themselves as having FA have higher rates of FA scores on the YFAS [61] . The endorsement of FA might influence the scale [22] .
In one study, patients with schizophrenia who were taking clozapine, which is known to induce weight gain as a secondary effect, had a higher prevalence of FA according to the YFAS [54] . Again, in this case, the only difference ought to be a higher appetite and this is not specifically measured by the YFAS. Perhaps this means that the scale is biased when given to people with a stronger appetite and modification of satiety, without this necessarily being FA.
One of the main limitations of the presented studies is that the bias arising from self-report of questionnaires used in the individual studies limits the findings of this review. The data presented in the studies provide information on the prevalence of YFAS scores in different groups. As the studies use a predefined cut-off and as we do not have sufficient information we cannot form conclusions about the clinical significance of FA diagnoses made by using only the YFAS.
We suggest more research is needed in this field and suggest examining the psychological processes of pathological eating from the perspective of behavioral addictions. Kardefelt-Winther et al. [74] suggested focusing on two components when defining behavioral addictions: (a) significant functional impairment or distress as a direct consequence of the behavior and (b) persistence over time. Significant functional impairment and distress is a criterion in the YFAS. Like persistence over time, it is also a symptom in BED and other EDs. In order not to pathologize common behavior, it is important to use the exclusion criteria suggested to ensure the behavior is not due to other factors. These exclusion criteria are as follows: (a) The behavior is not explained by an underlying disorder (depression, etc.), (b) the functional impairment does not result from willful choice, and (c) the behavior is not a temporary coping strategy [75]. Not using exclusion criteria when analyzing FA, as was the case for various studies in this review, is one potential criticism of their design. The behaviors were not examined in depth and instead the YFAS criteria were used to define and measure FA. It will also be important to add assessments of other psychological measures such as impulsivity that some studies, but not all, analyzed. For example, structured interviews would be helpful to study other factors, as would other statistical analyses such as item response theory [76] .
This review followed a strict systematic search protocol; however, it is not without limitations. Because strict eligibility criteria were applied in selecting relevant treatment studies, such as focusing on the last 3 years, they, therefore, represent only a sample of published studies on FA. The risk of bias in the individual studies was not assessed separately and this limits the findings of this review. Study populations were predominately female and overweight, limiting the generalizability of findings. More representative samples are needed to better understand the impact of FA symptoms in the general population.
CONCLUSION
The YFAS is a widely used evaluation tool in different populations, most often for patients with obesity who are searching for bariatric surgery. The prevalence of FA varies largely according to the population studied, which shows that it is dependent on sample recruitment methods. There is a clear association between elevated YFAS scores and ED, especially BED.
Rather than using the cut-off criteria of the YFAS, further studies should assess the individual items of the scale to examine the underlying mechanisms of this behavior from a clinical perspective. Analysis of behavioral addictions, as described earlier, could be helpful for establishing criteria to differentiate FA from other EDs.
